Showing results (251-260 of 267) with videos related to

Sort By:
Pageof 27
Journal of the National Cancer Institute|August 3, 2006
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECOJacobus Pfisterer, Béatrice Weber, Alexander Reuss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2019
Dilution of Molecular-Pathologic Gene Signatures by Medically Associated Factors Might Prevent Prediction of Resection Status After Debulking Surgery in Patients With Advanced Ovarian CancerFlorian Heitz, Stefan Kommoss, Roshan Tourani, et al.
International Journal of Molecular Sciences|August 12, 2022
Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World SettingRamona Erber, Miriam Angeloni, Robert Stöhr, et al.
The New England Journal of Medicine|December 30, 2011
A phase 3 trial of bevacizumab in ovarian cancerTimothy J Perren, Ann Marie Swart, Jacobus Pfisterer, et al.
The New England Journal of Medicine|February 28, 2019
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian NeoplasmsPhilipp Harter, Jalid Sehouli, Domenica Lorusso, et al.
Urology Practice|May 3, 2023
Development and validation of an objective scoring tool to evaluate surgical dissection: Dissection Assessment for Robotic Technique (DART)Erik B Vanstrum, Runzhuo Ma, Jacqueline Maya-Silva, et al.
Cancers|March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 TrialJean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Journal of Medical Genetics|April 14, 2019
Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883)Jan Hauke, Eric Hahnen, Stephanie Schneider, et al.
NPJ Digital Medicine|October 14, 2025
Leveraging Sarcopenia index by automated CT body composition analysis for pan cancer prognostic stratificationKatarzyna Borys, Johannes Haubold, Julius Keyl, et al.
Plos One|October 21, 2017
Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1)Philipp Harter, Jan Hauke, Florian Heitz, et al.
Pageof 27